Sanofi's LixiLan meets in Phase III

Sanofi (Euronext:SAN; NYSE:SNY) said LixiLan, its fixed-ratio combination of lixisenatide and Lantus insulin glargine, met the primary endpoint of significantly reducing HbA1c over Lantus or lixisenatide alone in the Phase III LixiLan-O study to treat Type II diabetes.

The 1,170-patient, 30-week trial evaluated a single daily injection of LixiLan in diabetes patients taking metformin. Sanofi said LixiLan's safety profile was similar to that of lixisenatide and Lantus. Spokesperson Susan Brooks told BioCentury the company is likely to release full results from the study next year. ...